Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-CHIK
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Subcutaneous
01
Overview
MV-CHIK is a recombinant live attenuated vaccine that uses the Schwarz strain of measles virus as a vector to express structural proteins of the chikungunya virus. Upon administration, the measles virus delivers chikungunya antigens directly to antigen-presenting cells such as dendritic cells and monocytes, inducing an immune response characterized by production of neutralizing antibodies against chikungunya. The vaccine has demonstrated good immunogenicity and safety in clinical trials, with robust induction of IgG1 and IgG3 antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Developed primarily for prevention of chikungunya fever—a mosquito-borne viral disease—MV-CHIK was created by Themis Bioscience in collaboration with Institut Pasteur[1][4][6][8].
- Other names
- measles-vectored chikungunya vaccinerecombinant live Schwarz-strain measles-vectored chikungunya vaccine
02
Targets
CHIKV E2/E1 (Chikungunya virus envelope protein)CHIKV structural polyprotein (Chikungunya virus structural polyprotein)
Beyond the preview
Go deeper on MV-CHIK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-CHIK.